UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|---|--|----------------------|----------------------------|------------------|--|
| 10/566,106 | 07/10/2006 | Walter Magerl | MERZ 48 PCT US | 9524 | |
| | 25666 7590 04/14/2009 THE FIRM OF HUESCHEN AND SAGE | | | EXAMINER | |
| SEVENTH FLOOR, KALAMAZOO BUILDING | | | RAMACHANDRAN, UMAMAHESWARI | | |
| 107 WEST MICHIGAN AVENUE KALAMAZOO, MI 49007 | | | ART UNIT | PAPER NUMBER | |
| | | | 1617 | | |
| | | | | | |
| | | | MAIL DATE | DELIVERY MODE | |
| | | | 04/14/2009 | PAPER | |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | Application No. | Applicant(s) | | | | |
|---|--|--|--|--|--|--|
| | 10/566,106 | MAGERL ET AL. | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| | UMAMAHESWARI RAMACHANDRAN | 1617 | | | | |
| The MAILING DATE of this communication app Period for Reply | ears on the cover sheet with the c | orrespondence address | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period was reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1,704(b). | ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timularly and will expire SIX (6) MONTHS from a cause the application to become ABANDONE | N. nely filed the mailing date of this communication. D (35 U.S.C. § 133). | | | | |
| Status | | | | | | |
| 1)⊠ Responsive to communication(s) filed on <u>26 Ja</u> | anuary 2006. | | | | | |
| | | | | | | |
| ,— | _ | | | | | |
| Disposition of Claims | | | | | | |
| 4) ✓ Claim(s) <u>25-50</u> is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ✓ Claim(s) <u>25-50</u> are subject to restriction and/or | vn from consideration. | | | | | |
| Application Papers | | | | | | |
| 9) The specification is objected to by the Examine | | | | | | |
| 10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner. | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). | | | | | | |
| 11) The oath or declaration is objected to by the Ex | - · · · · · | | | | | |
| Priority under 35 U.S.C. § 119 | | | | | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list | s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)). | on No ed in this National Stage | | | | |
| Attachment(a) | | | | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) | 4) Interview Summary | (PTO-413) | | | | |
| 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date | Paper No(s)/Mail Da 5) Notice of Informal P 6) Other: | nte | | | | |

DETAILED ACTION

Claims1-24 are cancelled and claims 25-50 are pending.

Lack of Unity

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Species of aminocyclohexane derivative compounds in a method of treating pain hypersensitivity and neuropathic pain.

The claims are deemed to correspond to the species listed above in the following manner:

Claims 25-33, 35, 36 correspond to aminocyclohexane derivative compounds and claims 34, 37-50 correspond to aminocyclohexane derivative, neramexane compound.

The following claim(s) are generic: Claims 125-33, 35, 36 are generic.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The technical feature shared by the above-listed species is that an aminocyclohexane derivative compounds such as neramexane is shown to be useful in method for delaying the onset or progression of a dementia associated with a disorder of the central nervous system (CNS), reducing the risk of such dementia, or treating

Art Unit: 1617

such dementia comprising administering to a patient in need of such treatment a first amount of an 1-aminocyclohexane derivative (U.S. 2004/0087658). Moebius teaches use of aminocyclohexane derivative compounds in a method of treating dementia. Accordingly, the species listed above do not share the same or a corresponding special technical feature as required for unity of invention.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. Applicant is required to a elect a species of aminocyclohexane derivative compound. The reply must also identify the claims readable on the elected species, including any claims subsequently added.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/566,106 Page 4

Art Unit: 1617

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Umamaheswari Ramachandran whose telephone number is 571-272-9926. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/SREENI PADMANABHAN/

Application/Control Number: 10/566,106

Page 5

Art Unit: 1617

Supervisory Patent Examiner, Art Unit 1617